Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

The Oncologist
Aditya BardiaDaniel S W Tan

Abstract

This multicenter, open-label, phase Ib study investigated the safety and efficacy of binimetinib (MEK inhibitor) in combination with buparlisib (phosphatidylinositol 3-kinase [PI3K] inhibitor) in patients with advanced solid tumors with RAS/RAF alterations. Eighty-nine patients were enrolled in the study. Eligible patients had advanced solid tumors with disease progression after standard therapy and/or for which no standard therapy existed. Evaluable disease was mandatory, per RECIST version 1.1 and Eastern Cooperative Oncology Group performance status 0-2. Binimetinib and buparlisib combinations were explored in patients with KRAS-, NRAS-, or BRAF-mutant advanced solid tumors until the maximum tolerated dose and recommended phase II dose (RP2D) were defined. The expansion phase comprised patients with epidermal growth factor receptor (EGFR)-mutant, advanced non-small cell lung cancer, after progression on an EGFR inhibitor; advanced RAS- or BRAF-mutant ovarian cancer; or advanced non-small cell lung cancer with KRAS mutation. At data cutoff, 32/89 patients discontinued treatment because of adverse events. RP2D for continuous dosing was buparlisib 80 mg once daily/binimetinib 45 mg twice daily. The toxicity profile of the combi...Continue Reading

References

Nov 13, 2003·Seminars in Oncology·Lee F AllenMark B Meyer
Nov 3, 2004·Nature Reviews. Molecular Cell Biology·Claudia WellbrockRichard Marais
Apr 11, 2009·BMC Cancer·Veronika AunerRobert Zeillinger
Jul 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus P HoeflichMark R Lackner
Aug 26, 2010·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Natsumi IraharaShuji Ogino
Dec 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johanna C BendellJosé Baselga
Dec 23, 2011·Molecular Cancer Therapeutics·Sauveur-Michel MairaCharles F Voliva
Jan 10, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael A DaviesKevin B Kim
Jan 21, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshio ShimizuAmita Patnaik
Mar 15, 2012·British Journal of Cancer·E J HaagensenD R Newell
Apr 27, 2012·BMC Research Notes·Heather Spencer FeigelsonC Sue Richards
Jun 22, 2012·Drugs·Raffaele CalifanoFederico Cappuzzo
Feb 28, 2013·Cancer Chemotherapy and Pharmacology·Carolyn D Britten
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy A YapJohann S de Bono
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philippe L BedardCristiana Sessa
Dec 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anthony W TolcherJohann S de Bono
Jun 29, 2015·Current Opinion in Pharmacology·Timothy A YapPaul Workman
Aug 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Celina García-GarcíaVioleta Serra
Aug 20, 2015·The New England Journal of Medicine·David M HymanJosé Baselga
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rachel N GrishamGopa Iyer
Sep 24, 2015·Biomarkers in Cancer·David Barras
Jun 25, 2016·Nature·Eusebio ManchadoScott W Lowe

❮ Previous
Next ❯

Citations

Sep 19, 2020·Expert Review of Gastroenterology & Hepatology·Jose Carlos RuffinelliVictor Moreno
Jul 8, 2020·International Journal of Molecular Sciences·Boris Y ShorningHelen B Pearson
Oct 31, 2020·Expert Opinion on Pharmacotherapy·Nicholas LenzeSiddharth Sheth
Jan 7, 2021·Journal of Hematology & Oncology·Jing HanQiming Wang
Dec 9, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Lingzhi ZhangYungen Xu
Mar 12, 2021·Frontiers in Immunology·Mahdi Abdoli ShadbadBehzad Baradaran
Mar 22, 2021·Clinical Colorectal Cancer·Ioannis A Voutsadakis
Apr 4, 2021·International Journal of Molecular Sciences·Rosalin MishraJoan T Garrett
May 1, 2021·Cancers·Alice IndiniGiorgio Bogani
Apr 19, 2021·Critical Reviews in Oncology/hematology·Silvia Rita VitalePaolo Vigneri
Apr 29, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroyuki Yasuda
May 28, 2021·ESMO Open·G PatelliA Sartore-Bianchi
Jul 3, 2021·Genes·Miriam Molina-ArcasJulian Downward
Jul 25, 2021·Journal of Hematology & Oncology·Kun ChenPeng Wang
Jul 14, 2021·Gynecologic Oncology·Phyllis van der PloegJurgen M J Piek
Aug 28, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies
exome sequencing

Clinical Trials Mentioned

NCT01363232
NCT01849874

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.